中國巨石(600176.SH):擬不低於1.352億美元掛牌轉讓巨石埃及24.99%股權
格隆匯1月23日丨中國巨石(600176.SH)公佈,公司全資子公司巨石集團有限公司(“巨石集團”)擬通過在北京產權交易所公開掛牌方式,轉讓其所持巨石埃及玻璃纖維股份有限公司(“巨石埃及”)24.99%股權,掛牌價格不低於1.352億美元;
在保證巨石集團對巨石埃及控制權及後期經營政策不發生變更的前提下,巨石集團適時為巨石埃及引入財務投資人,不會導致公司合併報表範圍發生變化。
若此次轉讓成功,公司將在加快國際化進程中得到有力的資金支持,在穩定資產負債率的同時探索出一條新型發展道路。此次轉讓符合公司整體發展戰略和經營計劃,有利於優化公司資產結構、合理配置資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.